<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403000</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000514492</org_study_id>
    <secondary_id>RPCI-I-34904</secondary_id>
    <nct_id>NCT00403000</nct_id>
  </id_info>
  <brief_title>Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy</brief_title>
  <official_title>Phase II Study of Dutasteride in Prostate Cancer Recurrent During Androgen Deprivation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well dutasteride works in treating patients with&#xD;
      recurrent prostate cancer that did not respond to androgen-deprivation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Evaluate the time to disease progression in patients with recurrent prostate cancer that&#xD;
           progressed during androgen-deprivation therapy who are treated with dutasteride.&#xD;
&#xD;
        -  Evaluate the toxicity of dutasteride in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the serum prostate-specific antigen (PSA) level and objective radiographic&#xD;
           response rate in patients treated with dutasteride.&#xD;
&#xD;
        -  Determine the survival of patients treated with dutasteride.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with dutasteride.&#xD;
&#xD;
      OUTLINE: Patients receive oral dutasteride once daily until disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline and then every 3 months thereafter.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Every 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Daily while on Treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response (complete and partial) rate and serum prostate-specific antigen levels</measure>
    <time_frame>Every 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Every 12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutasteride</intervention_name>
    <description>Oral</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of prostate cancer&#xD;
&#xD;
               -  Asymptomatic progressive disease despite androgen-deprivation therapy&#xD;
&#xD;
                    -  Progression must occur during androgen-deprivation therapy comprising&#xD;
                       orchiectomy or luteinizing hormone-releasing hormone (LHRH) analogue with or&#xD;
                       without antiandrogen AND after antiandrogen withdrawal&#xD;
&#xD;
                         -  Concurrent LHRH monotherapy (i.e., LHRH analogs, such as leuprolide&#xD;
                            acetate or goserelin) required in patients who did not undergo prior&#xD;
                            bilateral orchiectomy to assure testicular androgen suppression&#xD;
&#xD;
          -  Recurrent disease, as indicated by at least 1 of the following:&#xD;
&#xD;
               -  Prostate-specific antigen (PSA) at baseline ≥ 2.0 ng/mL&#xD;
&#xD;
               -  Biopsy-confirmed local recurrence&#xD;
&#xD;
               -  Increase in size of measurable lesions on radiographic study&#xD;
&#xD;
               -  New lesion on a nuclear bone scan&#xD;
&#xD;
               -  Two successive increases in serum PSA measured at least 1 week apart&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  SGOT ≤ 4 times upper limit of normal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy and recovered&#xD;
&#xD;
          -  At least 28 days since prior flutamide OR at least 42 days since prior bicalutamide or&#xD;
             nilutamide&#xD;
&#xD;
               -  Patients who have previously progressed despite antiandrogen withdrawal and who&#xD;
                  have started antiandrogens without reduction of serum PSA are eligible without&#xD;
                  requiring a 28- or 42-day washout interval after antiandrogen withdrawal&#xD;
&#xD;
          -  No other prior systemic therapies, except androgen-deprivation therapy (i.e.,&#xD;
             orchiectomy or LHRH analogues only) or antiandrogens&#xD;
&#xD;
               -  Surgery, brachytherapy, external-beam radiotherapy, and cryotherapy are not&#xD;
                  considered systemic therapies&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No concurrent use of any of the following:&#xD;
&#xD;
               -  Finasteride&#xD;
&#xD;
               -  Other investigational 5α-reductase inhibitors&#xD;
&#xD;
               -  Anabolic steroids&#xD;
&#xD;
               -  Alpha-receptor blockers (e.g., indoramin, tamsulosin hydrochloride, prazosin,&#xD;
                  terazosin, alfuzosin hydrochloride, and doxazosin)&#xD;
&#xD;
               -  Drugs with antiandrogenic properties (e.g., spironolactone, flutamide,&#xD;
                  bicalutamide, cimetidine, ketoconazole, metronidazole, and progestational agents)&#xD;
&#xD;
               -  Products containing selenium ≥ 75 mcg or vitamin E ≥ 100 IU&#xD;
&#xD;
               -  Saw palmetto&#xD;
&#xD;
               -  EG6761&#xD;
&#xD;
          -  No concurrent radiotherapy, including palliative radiotherapy for pain control&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L. Mohler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. doi: 10.1016/j.juro.2008.10.014. Epub 2008 Dec 16.</citation>
    <PMID>19091347</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>November 21, 2006</study_first_submitted>
  <study_first_submitted_qc>November 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2006</study_first_posted>
  <last_update_submitted>April 30, 2013</last_update_submitted>
  <last_update_submitted_qc>April 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

